Collaboration-with-OxfordBioTherapeutics

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the ClinicThe collaboration for the discovery of novel selective tumor targets for Boehringer Ingelheim ’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by Oxford BioTherapeutics’ proprietary OGAP® (Oxford Genome Anatomy Project) target discovery platform, is the latest in a series of collaborations that strengthens Boehringer Ingelheim’s position and leading asse ts in cancer immunology. 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news